Publicações

1. Bressan RA, Bigliani V, Pilowsky LS. Neuroimaging of D2 dopamine receptors in schizophrenia. Rev Bras Psiquiatria 23(Suppl 1): 46-49, 2001b.
2. Bressan RA, Costa DC, Jones HM, Ell PJ, Pilowsky LS. Typical antipsychotic drugs - D2 receptor blockade and depressive symptoms in schizophrenia. Schizophr Res 56:31-36, 2002.
3. Bressan RA, Erlandsson K, Jones HM, Mulligan RM, Ell PJ, Pilowsky LS. Optimising Limbic Selective D2/D3 Receptor Occupancy by Risperidone – a [123I]-epidepride SPET study. J Clin Psychopharmacol 23(1):5-14, 2003a.
4. Bressan RA, Erlandsson K, Jones HM, Mulligan RM, Flanaghan R, Ell PJ, Pilowsky LS. Selective D2/D3 dopamine receptor occupancy is sufficient for atypical antipsychotic effect. An in vivo quantitative [123I]-epidepride single photon emission tomography (SPET) study of amisulpride treated patients. Am J Psychiatry 160:1413-20, 2003e.
5. Bressan RA, Erlandsson K, Mulligan RS, Gunn RN, Cunningham VJ, Owens J, Cullum I, Ell PJ, Pilowsky LS. A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261. Nucl Med Biol 31:155-164, 2004a.
6. Bressan RA, Erlandsson K, Mulligan RS, Gunn RN, Cunningham VJ, Owens J, Ell PJ, Pilowsky LS. Evaluation of NMDA receptors in vivo in schizophrenic patients with [123I]CNS 1261 and SPET: preliminary findings. Ann N Y Acad Sci 1003:364-7. 2003d.
7. Bressan RA, Erlandsson K, Spencer EP, Ell PJ, Pilowsky LS. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacol (in press)
8. Bressan RA, Jones HM, Ell PJ, Pilowsky LS. Typical antipsychotic drugs and depressive symptoms in schizophrenia. Am J Psychiatry 158(6): 972-973, 2001a.
9. Bressan RA, Jones HM, Pilowsky LS. Atypical antipsychotic drugs and Tardive Dyskinesia – relevance of D2 receptor affinity. J Psychopharmacol 18(1): 109-112, 2004b.
10. Bressan RA, Pilowsky LS. Imaging the glutamatergic system in vivo – relevance to schizophrenia. Eur J Nucl Med 27:1723-1731, 2000.
11. Bressan RA, Pilowsky LS. The Glutamatergic Hypothesis of Schizophrenia. Rev Bras Psiquiatria 25(3):177-183, 2003.
12. Brebion G., David AS, Bressan RA, Pilowsky LS. Word frequency effects on free recall and recognition in patients with schizophrenia. J Psychiatric Res (in press).
13. Brébion G, Bressan RA, Amador X, Malaspina D, Gorman JM. Medications and verbal memory impairment in schizophrenia – the role of anticholinergic drugs. Psychol Med 34:360-374, 2004.
14. Erlandsson K, Bressan RA, Mulligan RM, Ell PJ, Cunningham VJ, Pilowsky LS. Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-affinity ligand [123I]epidepride: resolving conflicting findings. Neuroimage 19:1205-14,2003a.
15. Erlandsson K, Bressan RA, Mulligan RS, Gunn RN, Cunningham VJ, Owens J, Wyper D, Ell PJ, Pilowsky LS. Kinetic modelling of [123I]-CNS 1261 – a potential SPET tracer for the NMDA receptor. Nucl Med Biol 30:441-454, 2003b.
16. Fujita M, Innis RB. In vivo Molecular Imaging: ligand development and research applications. In: Neuropsychopharmacology - The Fifth Generation of Progress. Ed Borroni E and Kupfer DJ. New York, Raven Press Ltd, pp 411-425, 2000.
17. Lacerda AL, Hardan AY, Yorbik O, Keshavan MS (2003): Measurement of the orbitofrontal cortex: a validation study of a new method. Neuroimage 19:665-73.
18. Lacerda AL, Keshavan MS, Hardan AY, et al (2004b): Structural evaluation of the orbitofrontal cortex in major depressive disorder. Biol Psychiatry.
19. Lacerda, Alt, Nicoletti, Ma, Brambilla, P, Sassi, Rb, Mallinger, Ag, Frank, E, Kupfer, Dj, Keshavan, Ms, Soares, Jc. Anatomical MRI study of basal ganglia in Major Depressive Disorder. Psychiatry Research Neuroimaging, 2004a.
20. Lacerda, Alt, Dalgalarrondo, P, Camargo, Ee. Achados de neuroimagem no transtorno obsessivo-compulsivo. Revista Brasileira de Psiquiatria, v.23, n.supl 1, p.24-27, 2001.
21. Cunha PJ, Novaes MA [Neurocognitive assessment in alcohol abuse and dependence: implications for treatment] Rev Bras Psiquiatr. 2004 May;26 Suppl 1:23-7. Epub 2005 Jan 04. Portuguese. PMID: 15729440 [PubMed - in process].